Cannabis legalization is advancing globally, often commencing with medical cannabis, the establishment of social cannabis clubs, and the availability of recreational cannabis. Even this segmented market story sounds complicated, but wait, there's more! What we're referring to is the hemp-derived cannabinoid market, fraught with synthetic cannabinoids. Some refer to them as 'hempnoids' (for hemp-derived), while others label them 'frankenoids' or 'zombienoids', drawing parallels to Frankenstein and Zombies. Yet others proudly champion synthetic cannabinoids, blurring the line between defending them all, including the notorious 'Kush' and 'Spice' cannabinoids. All of this is rooted in profit-making rather than improving health and wellness. Capitalism is, in part, driven by marketing (and hype), making things desirable, aesthetically pleasing, and socially acceptable. While the tightly regulated medical and recreational high-THC cannabis markets have endeavored to strike a balance between gimmicks, ethics, and science, the unregulated and illicit markets are just the opposite, rife with misinformation and questionable certificates of authenticity (COAs). The biggest loser in all of this—be it synthetic, semi-synthetic, decarboxylated, non-decarboxylated, hemp-derived, or China-imported—is the consumer and healthcare practitioner, left grappling with numerous traditionally unproven medical cannabis claims.
As debates on the legality of 'hempnoids', their potential benefits or long-term harms, and the absence of standardized methods of preparation designed for human consumption continue, cannabis education and consumer safety remain top priorities. Labroots 7th Annual Cannabis Virtual Series will shed light on these issues with some of the foremost experts in the field. For example, the series will feature keynote continuous medical education (CME) talks from Jokūbas Ziburkus, PhD and Ethan Russo, MD.
Dr. Ziburkus will lay the groundwork by explaining the complex landscape of the cannabis plant, cannabinoids, previously attempted taxonomy systems aimed at categorizing and visually representing cannabinoids to consumers and will introduce a new system and technology for cannabis product taxonomy that could benefit the entire industry, with a particular focus on consumers. Dr. Ziburkus's talk will be live, including a Q&A session. Dr. Ethan Russo's keynote will delve into cannabinoid hyperemesis syndrome, which is on the rise, and we hope he will also discuss his latest work on mitigating THC effects with terpenes. Additionally, the conference will feature renowned medical cannabis doctors, scientists, and industry leaders, including Bonni Goldstein, MD, Medical Director of Canna-Centers Wellness & Education, Len May, MSc, CEO and Co-Founder of Endocanna Health, Guillermo Moreno-Sanz, PhD, Scientific Director of Khiron Life Sciences, Shaun R. Opie, PhD, Managing Partner of E4 Bioscience, Alexey Peshkovsky, PhD, President, and Chief Scientific Officer of Industrial Sonomechanics, LLC, Anthony Repay, MS, Laboratory Director of Method Testing Labs, and Michelle Weiner, DO, MPH, Director of Integrative Pain at NeuroPain Health discussing a range of topics from pain management to cannabis compliance.
For more information on this series and to register: Labroots 7th Annual Event in the 2024 Cannabis Sciences Virtual Event Series, on April 17th, 2024.
Copyright Bluebonnet Wellness 2024 © by Adendox, LLC.